Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$40.64 USD
+0.49 (1.22%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $40.54 -0.10 (-0.25%) 7:36 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
Tandem Diabetes Care, Inc. [TNDM]
Reports for Purchase
Showing records 121 - 140 ( 240 total )
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Tandem 1Q17 Stands up to the Challenge; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Discontinuation of Research Coverage
Provider: Feltl & Company
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
1Q17 Preview: Outperforming in MedTech Year-to-Date Reflects Stable Fundamentals That Should Continue Throughout 2017
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Best-In-Class Insulin Pump Portfolio, Upcoming Inflection Point in Sales Growth, and Attractive Valuation; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Q4 inline, secondary coming, but pipeline on track - reiterate BUY, target to $4.50
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Medical Devices: Diabetes Market Implications from JNJ''s Potential Exit
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
CMS to Reimburse DXCM''s G5; Positive for DXCM, PODD, TNDM; Negative for MDT
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Q3 misses estimates, confusion in marketplace, lower to BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
3Q16 Disappoints, But We Continue To View Tandem''s Insulin Pump Technology As Best-in-Class; Reducing PT to $11; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Highlights from JNJ''s 3Q16 Results Bode Well for the MedTech Sector; Most Positive Read
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
3Q16 Preview: Stable Growth Trends Through The End of 2016
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Diabetes Technology Panel Highlights The Opportunities That Lie Ahead
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Medical Devices - Day 1: Key Takeaways from the PacGrow Healthcare Conference
Provider: WEDBUSH SECURITIES INC.
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Q2 roughly inline -t:slim X2 a master stroke - reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Tandem Diabetes Care, Inc.
Industry: Medical - Instruments
Strong Underlying Growth - New Insulin Pump Platform Suggest More Share Gains To Come; Reiterate OP
Provider: WEDBUSH SECURITIES INC.